Allergan, DMRF continue collaboration to bring awareness to dystonia

Allergan will continue its collaborative efforts with Dystonia Medical Research Foundation (DMRF) to support patients with dystonia by conducting a survey that will assess cervical dystonia awareness, its symptoms and options for treatment that will inspire education and the correct diagnosis of the condition, which can often be disabling.

"Our partnership with Allergan on this survey will support patients with cervical dystonia and their families by shedding light on the lack of awareness of the condition," DMRF President Art Kessler said. "It is imperative that patients have accurate information about cervical dystonia in order to seek the appropriate care and treatment options. Equally as critical, is continuing to work with a healthcare provider."

Dystonia is a chronic disorder that affect movement. Approximately 250,000 people across the U.S. have been diagnosed with the condition.

"Allergan is committed to supporting patients with cervical dystonia and educating the public about this condition in order to encourage proper diagnosis and treatment," BOTOX Senior Vice President of Global Drug Development Dr. Mitchell Brin said. "We value our continued partnership with the DMRF to raise awareness of cervical dystonia, potential treatment options and the importance of talking to your doctor."